We are developing bi-specific antibodies aimed to kill tumor cells, based on MOSPD2 as a target whose expression is induced in multiple tumors.

MOSPD2 can be found in many types of solid tumors, and it seems to be highly expressed on tumor cells when they start invading tissues or creating metastatic lesions. This correlates with the role we identified for MOSPD2 as a key regulator of cell motility in tumor cells. Our preliminary data indicate that knock-out of MOSPD2 in tumor cells may reduce metastasis by 95% in some pre-clinical settings.

In July 2018, we published a manuscript demonstrating, for the first time, that MOSPD2 can play a major role in breast cancer cell migration and metastasis. Histological analysis of human specimens shows that MOSPD2 levels were correlated with the stage of tumor invasiveness, and were profoundly elevated in invasive and metastatic breast cancer. 

Based on these findings, our approach is to utilize MOSPD2 as a target for attacking the tumor cells in the treatment of late-stage breast cancer and other tumor types.

For additional scientific data see: PUBLICATIONS